The study will enrol up to 40 participants across a maximum of five clinical sites in the US.

AngioDynamics ANGO recently announced that the FDA has approved its IDE application to initiate the RELIEF study, which will ...

OXFORD, UK / ACCESS Newswire / June 15, 2026 /Fine Treatment has highlighted increasing interest in non-invasive therapeutic ...

(NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today ...

Frequent urination, urgency and waking up at night to urinate are often blamed on an enlarged prostate. However, doctors say ...

U.S. Market Projected to Hit USD 7.06 Billion by 2035 While Europe Market Expected to Reach USD 6.42 Billion as Aging Male Population Fuels Demand for Advanced BPH Therapies.Austin, United States, May ...

For men with benign prostatic hyperplasia (BPH), prostatic artery embolization (PAE) is safe and effective over 24 months of follow-up, according to a study published online Sept. 4 in Cardiovascular ...

THE acid phosphatase content of malignant prostatic tissue is regarded as an example of the retention by the neoplastic growth of a biochemical characteristic of the fully differentiated tissue of ...

High-grade prostatic intraepithelial neoplasia (HGPIN) is the most likely precursor of prostatic adenocarcinoma according to virtually all available evidence. This lesion is characterized by cellular ...